• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SCHEDULE 13G filed by Galecto Inc.

    2/17/26 7:17:39 PM ET
    $GLTO
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $GLTO alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    Galecto, Inc.

    (Name of Issuer)


    Common Stock, $0.00001 par value per share

    (Title of Class of Securities)


    36322Q206

    (CUSIP Number)


    02/09/2026

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox not checked   Rule 13d-1(b)
    Checkbox checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    36322Q206


    1Names of Reporting Persons

    Venrock Healthcare Capital Partners III, L.P.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    3,603,595.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    3,603,595.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    3,603,595.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    6.0 %
    12Type of Reporting Person (See Instructions)

    PN


    SCHEDULE 13G

    CUSIP No.
    36322Q206


    1Names of Reporting Persons

    VHCP Co-Investment Holdings III, LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    3,603,595.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    3,603,595.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    3,603,595.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    6.0 %
    12Type of Reporting Person (See Instructions)

    OO


    SCHEDULE 13G

    CUSIP No.
    36322Q206


    1Names of Reporting Persons

    Venrock Healthcare Capital Partners EG, L.P.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    3,603,595.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    3,603,595.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    3,603,595.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    6.0 %
    12Type of Reporting Person (See Instructions)

    PN


    SCHEDULE 13G

    CUSIP No.
    36322Q206


    1Names of Reporting Persons

    VHCP Management III, LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    3,603,595.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    3,603,595.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    3,603,595.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    6.0 %
    12Type of Reporting Person (See Instructions)

    OO


    SCHEDULE 13G

    CUSIP No.
    36322Q206


    1Names of Reporting Persons

    VHCP Management EG, LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    3,603,595.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    3,603,595.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    3,603,595.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    6.0 %
    12Type of Reporting Person (See Instructions)

    OO


    SCHEDULE 13G

    CUSIP No.
    36322Q206


    1Names of Reporting Persons

    Nimish Shah
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    3,603,595.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    3,603,595.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    3,603,595.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    6.0 %
    12Type of Reporting Person (See Instructions)

    IN


    SCHEDULE 13G

    CUSIP No.
    36322Q206


    1Names of Reporting Persons

    Bong Y. Koh
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    3,603,595.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    3,603,595.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    3,603,595.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    6.0 %
    12Type of Reporting Person (See Instructions)

    IN


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    Galecto, Inc.
    (b)Address of issuer's principal executive offices:

    75 State Street, Suite 100, Boston, MA, 02109.
    Item 2. 
    (a)Name of person filing:

    The names of the persons filing this report (collectively, the "Reporting Persons") are: Venrock Healthcare Capital Partners III, L.P. ("VHCP III") VHCP Co-Investment Holdings III, LLC ("VHCP Co-Investment III") Venrock Healthcare Capital Partners EG, L.P. ("VHCP EG") VHCP Management III, LLC ("VHCP Management III") VHCP Management EG, LLC ("VHCP Management EG") Nimish Shah ("Shah") Bong Koh ("Koh") The Reporting Persons are members of a group for the purposes of this Schedule 13G.
    (b)Address or principal business office or, if none, residence:

    New York Office: 7 Bryant Park, 23rd Floor New York, NY 10018 Palo Alto Office: 3340 Hillview Avenue Palo Alto, CA 94304
    (c)Citizenship:

    All of the entities were organized in Delaware. Shah and Koh are both United States citizens.
    (d)Title of class of securities:

    Common Stock, $0.00001 par value per share
    (e)CUSIP No.:

    36322Q206
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox not checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    Row 9 of each Reporting Person's cover page to this Schedule 13G sets forth the aggregate number of shares of common stock of the Issuer beneficially owned by such Reporting Person and is incorporated by reference. The Reporting Persons' ownership of the Issuer's securities consists of (i) 692,909 shares of common stock held by VHCP III, (ii) 69,331 shares of common stock held by VHCP Co-Investment III, and (iii) 2,841,355 shares of common stock held by held by VHCP EG. VHCP Management III is the general partner of VHCP III and the manager of VHCP Co-Investment III. VHCP Management EG is the general partner of VHCP EG. Messrs. Shah and Koh are the voting members of VHCP Management III and VHCP Management EG.
    (b)Percent of class:

    Row 11 of each Reporting Person's cover page to this Schedule 13G sets forth the percentages of the shares of common stock of the Issuer beneficially owned by such Reporting Person and is incorporated by reference. The percentage set forth in each row 11 is based upon 60,232,620 shares of common stock outstanding as of February 12, 2026, as reported in the Issuer's prospectus supplement dated February 10, 2026 filed with the Securities and Exchange Commission (the "SEC") on February 11, 2026.
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    Row 5 of each Reporting Person's cover page to this Schedule 13G sets forth the sole power to vote or to direct the vote of securities of the Issuer beneficially owned by such Reporting Person and is incorporated by reference.

     (ii) Shared power to vote or to direct the vote:

    Row 6 of each Reporting Person's cover page to this Schedule 13G sets forth the shared power to vote or to direct the vote of securities of the Issuer beneficially owned by such Reporting Person and is incorporated by reference.

     (iii) Sole power to dispose or to direct the disposition of:

    Row 7 of each Reporting Person's cover page to this Schedule 13G sets forth the sole power to dispose or to direct the disposition of securities of the Issuer beneficially owned by such Reporting Person and is incorporated by reference.

     (iv) Shared power to dispose or to direct the disposition of:

    Row 8 of each Reporting Person's cover page to this Schedule 13G sets forth the shared power to dispose or to direct the disposition of securities of the Issuer beneficially owned by such Reporting Person and is incorporated by reference.

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Not Applicable
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    Not Applicable
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    Venrock Healthcare Capital Partners III, L.P.
     
    Signature:/s/ Sherman G. Souther
    Name/Title:By VHCP Management III, LLC, its General Partner, By Sherman G. Souther, Authorized Signatory
    Date:02/17/2026
     
    VHCP Co-Investment Holdings III, LLC
     
    Signature:/s/ Sherman G. Souther
    Name/Title:By VHCP Management III, LLC, its Manager, By Sherman G. Souther, Authorized Signatory
    Date:02/17/2026
     
    Venrock Healthcare Capital Partners EG, L.P.
     
    Signature:/s/ Sherman G. Souther
    Name/Title:By VHCP Management EG, LLC, its General Partner, By Sherman G. Souther, Authorized Signatory
    Date:02/17/2026
     
    VHCP Management III, LLC
     
    Signature:/s/ Sherman G. Souther
    Name/Title:By Sherman G. Souther, Authorized Signatory
    Date:02/17/2026
     
    VHCP Management EG, LLC
     
    Signature:/s/ Sherman G. Souther
    Name/Title:By Sherman G. Souther, Authorized Signatory
    Date:02/17/2026
     
    Nimish Shah
     
    Signature:/s/ Sherman G. Souther
    Name/Title:By Sherman G. Souther, Attorney-in-fact
    Date:02/17/2026
     
    Bong Y. Koh
     
    Signature:/s/ Sherman G. Souther
    Name/Title:By Sherman G. Souther, Attorney-in-fact
    Date:02/17/2026
    Exhibit Information

    Exhibit 24.1 Power of Attorney for Bong Koh Exhibit 24.2 Power of Attorney for Nimish Shah Exhibit 99.1 Joint Filing Agreement

    Get the next $GLTO alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $GLTO

    DatePrice TargetRatingAnalyst
    2/17/2026$45.00Buy
    UBS
    1/7/2026$46.00Outperform
    Leerink Partners
    12/1/2025$32.00Buy
    Guggenheim
    8/6/2021$12.00 → $7.00Outperform
    Credit Suisse
    More analyst ratings

    $GLTO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Bruno Julianne converted options into 129,000 shares, increasing direct ownership by 1,606% to 137,032 units (SEC Form 4)

    4 - Galecto, Inc. (0001800315) (Issuer)

    2/12/26 6:05:08 AM ET
    $GLTO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Fairmount Funds Management Llc converted options into 8,713,000 shares (SEC Form 4)

    4 - Galecto, Inc. (0001800315) (Issuer)

    2/12/26 6:03:41 AM ET
    $GLTO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Operating Officer Sattarzadeh Sherwin was granted 190,376 shares (SEC Form 4)

    4 - Galecto, Inc. (0001800315) (Issuer)

    1/26/26 9:04:44 PM ET
    $GLTO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GLTO
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Galecto Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares for Gross Proceeds of $316.3 Million

    BOSTON, Feb. 12, 2026 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ:GLTO), a biopharmaceutical company focused on developing novel therapeutics to redefine the treatment paradigm for people living with blood cancers, today announced the closing of its previously announced underwritten public offering of 16,644,737 shares of its common stock, including the full exercise of the underwriters' option to purchase up to 2,171,052 additional shares, at a public offering price of $19.00 per share. The aggregate gross proceeds to Galecto from the offering were approximately $316.3 million, before deducting underwriting discounts and commissions and offering expenses payable by Galecto. Jefferies, Leer

    2/12/26 4:01:00 PM ET
    $GLTO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Galecto Announces Pricing of $275 Million Underwritten Public Offering

    BOSTON, Feb. 10, 2026 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ:GLTO), a biopharmaceutical company focused on developing novel therapeutics to redefine the treatment paradigm for people living with blood cancers, today announced the pricing of its previously announced underwritten public offering of shares of its common stock. Galecto is selling a total of 14,473,685 shares of common stock at a public offering price of $19.00 per share. In addition, Galecto has granted the underwriters a 30-day option to purchase an additional 2,171,052 shares of common stock at the public offering price, less underwriting discounts and commissions. The gross proceeds to Galecto from the offering are expec

    2/10/26 10:42:03 PM ET
    $GLTO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Galecto Announces Proposed Underwritten Public Offering of Common Stock and Preferred Stock

    BOSTON, Feb. 10, 2026 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ:GLTO), a biopharmaceutical company focused on developing novel therapeutics to redefine the treatment paradigm for people living with blood cancers, today announced that it has commenced an underwritten public offering of shares of its common stock and, in lieu of common stock to certain investors that so choose, Series C non-voting convertible preferred stock. All of the securities are being offered by Galecto. In addition, Galecto intends to grant the underwriters a 30-day option to purchase additional shares of its common stock. Each share of Series C preferred stock will be convertible into 1,000 shares of common stock at

    2/10/26 4:04:47 PM ET
    $GLTO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GLTO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    UBS initiated coverage on Galecto with a new price target

    UBS initiated coverage of Galecto with a rating of Buy and set a new price target of $45.00

    2/17/26 8:59:23 AM ET
    $GLTO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Leerink Partners initiated coverage on Galecto with a new price target

    Leerink Partners initiated coverage of Galecto with a rating of Outperform and set a new price target of $46.00

    1/7/26 8:34:02 AM ET
    $GLTO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Guggenheim initiated coverage on Galecto with a new price target

    Guggenheim initiated coverage of Galecto with a rating of Buy and set a new price target of $32.00

    12/1/25 8:28:46 AM ET
    $GLTO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GLTO
    SEC Filings

    View All

    SEC Form SCHEDULE 13G filed by Galecto Inc.

    SCHEDULE 13G - Galecto, Inc. (0001800315) (Subject)

    2/17/26 7:17:39 PM ET
    $GLTO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13D/A filed by Galecto Inc.

    SCHEDULE 13D/A - Galecto, Inc. (0001800315) (Subject)

    2/11/26 6:11:02 PM ET
    $GLTO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 8-K filed by Galecto Inc.

    8-K - Galecto, Inc. (0001800315) (Filer)

    2/11/26 5:10:21 PM ET
    $GLTO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GLTO
    Leadership Updates

    Live Leadership Updates

    View All

    Galecto Highlights Key Strategic Priorities and Anticipated 2026 Milestones

    DMR-001, a potentially best-in-class mutant calreticulin ("mutCALR") targeting monoclonal antibody, on track for expected IND submission, or equivalent, in mid-2026 with anticipated first-in-human dosing via subcutaneous administrationRecent addition of deep hematology/oncology drug development experience with the appointment of a Chief Operating Officer and Chief Medical OfficerPipeline of additional candidates advancing to the clinic, with first IND submission of DMR-002 expected in second half of 2026Cash balance, following $285M raised in the November PIPE, provides financial runway into 2029 to support multiple data milestones, including Ph1 clinical proof-of-concept data for DMR-001 an

    1/12/26 8:00:00 AM ET
    $GLTO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Galecto Announces Key Additions to Leadership Team

    Deep hematology/oncology drug development experience added with the appointment of Sherwin Sattarzadeh as Chief Operating Officer and Becker Hewes as Chief Medical Officer DMR-001, a potentially best-in-class mutant calreticulin ("mutCALR") targeting monoclonal antibody, on track for IND submission in mid-2026 with anticipated first-in-human dosing via subcutaneous administration Cash balance, including $285 million raised in November 2025 PIPE, provides financial runway into 2029 to support multiple data milestones, including Ph1 clinical proof-of-concept data for DMR-001 anticipated in 2027 BOSTON, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Galecto, Inc. ("Galecto" or the "Company"), a biotech

    1/6/26 8:00:00 AM ET
    $GLTO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Galecto Strengthens Board of Directors with Appointment of Dr. Amy Wechsler

    BOSTON, Oct. 15, 2024 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ:GLTO), a clinical-stage biotechnology company focused on the development of novel treatments for cancer and fibrosis, today announced the appointment of Dr. Amy Wechsler to its Board of Directors. Dr. Wechsler brings a unique combination of expertise and a proven track record of leadership in the healthcare industry. "We are thrilled to welcome Dr. Wechsler to our Board of Directors," said Dr. Carl Goldfischer, Chair of the Board of Galecto. "Amy is a distinguished physician who has board certification in both dermatology and psychiatry. Her experience guiding companies through critical growth stages make her an important add

    10/15/24 8:30:00 AM ET
    $GLTO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GLTO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Galecto Inc.

    SC 13G/A - Galecto, Inc. (0001800315) (Subject)

    11/7/24 3:07:49 PM ET
    $GLTO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Galecto Inc.

    SC 13G - Galecto, Inc. (0001800315) (Subject)

    11/7/24 2:55:56 PM ET
    $GLTO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Galecto Inc.

    SC 13G/A - Galecto, Inc. (0001800315) (Subject)

    8/29/24 5:59:56 PM ET
    $GLTO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GLTO
    Financials

    Live finance-specific insights

    View All

    Galecto Completes Strategic Review to Focus on Oncology and Liver Disease and Acquires Acute Myeloid Leukemia Preclinical Asset from Bridge Medicines

    Galecto will focus on cancer and liver disease, leveraging existing clinical stage asset GB1211Bolsters pipeline by obtaining global rights to BRM-1420, a novel dual ENL-YEATS and FLT3 inhibitor for multiple genetic subsets of acute myeloid leukemia (AML)BRM-1420 has the potential for enhanced clinical effectiveness compared to FLT3 inhibitors alone and has shown synergistic effects with SOC in preclinical models BOSTON, Oct. 07, 2024 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ:GLTO), a clinical-stage biotechnology company focused on the development of novel treatments for cancer and fibrosis, today announced that, following an intensive strategic review process, Galecto has determined to f

    10/7/24 8:45:46 AM ET
    $GLTO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Galecto Presents Positive Clinical Data at AASLD Showing Statistically Significant Improvements in Important Liver Parameters in Decompensated Cirrhosis Patients

    Statistically significant reductions observed in ALT, AST and GGT, supporting further development of GB1211 in severe liver diseasesFindings to be discussed in a conference call and virtual webinar today, November 8, 2022, at 8 a.m. ET BOSTON, Nov. 08, 2022 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ:GLTO), a clinical-stage biotechnology company and a world leader in galectin biology focused on the development of novel treatments for fibrosis and cancer, announced it will discuss topline data and additional analyses from its recently completed Phase 1b/2a GULLIVER-2 trial (NCT05009680), including the observed statistically significant signs of liver protection, in a conference call and virt

    11/8/22 6:00:00 AM ET
    $GLTO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Galecto to Present Topline Data from GULLIVER-2 Clinical Trial Showing GB1211 Reduced Signs of Liver Impairment at AASLD's The Liver Meeting® 2022

    Late-breaking oral and poster presentations include clinical and preclinical data related to GULLIVER-2 clinical trialGalecto to host a webinar at 8:00 a.m. ET on Tuesday, November 8, 2022 to discuss expanded topline data and analysis BOSTON, Oct. 31, 2022 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ:GLTO), a clinical-stage biotechnology company and a world leader in galectin biology focused on the development of novel treatments for fibrosis and cancer, today announced it will present data from its recently completed Phase 1b/2a GULLIVER-2 trial at the American Association for the Study of Liver Diseases' (AASLD) The Liver Meeting 2022 being held in Washington, D.C. on November 4-8, 2022. G

    10/31/22 8:00:00 AM ET
    $GLTO
    Biotechnology: Pharmaceutical Preparations
    Health Care